Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

Core Insights - Catalyst Pharmaceuticals, Inc. has appointed Dr. Daniel Curran to its Board of Directors, bringing over 25 years of pharmaceutical experience [1][2] - Dr. Curran's expertise includes strategy, business development, and rare disease knowledge, which will support Catalyst's growth strategy [3][4] - The company has a strong foundation in delivering innovative therapies for rare diseases and aims to expand its global presence [7] Company Overview - Catalyst Pharmaceuticals is focused on improving the lives of patients with rare diseases through innovative therapies [7] - The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list [7] - Catalyst emphasizes patient care and accessibility, providing comprehensive support services to ensure patients receive necessary treatments [7] Leadership Background - Dr. Curran has held significant roles at Takeda Pharmaceutical Company, including Senior Vice President and Head of the Rare Genetics and Hematology Therapeutic Area Unit [3][4] - He has also served in leadership positions at Millennium Pharmaceuticals and DuPont Merck Pharmaceuticals [4][5] - Dr. Curran holds an M.D. from the University of Pennsylvania, an M.B.A. from The Wharton School, and a B.S. in chemistry from King's College [6]